Current notable studies focus on its potential in treating infected or injured eyes, such as cases involving Pseudomonas aeruginosa -induced keratitis, and the facilitation of corneal wound healing [5, 6]
This inextricably links gliotoxin/BmGT formation to the cellular Methyl/Met cycle via GtmA (Owens et al., 2015) (Figure 2) and leads to the conclusion that biosynthesis and dissipation of the disulfide-containing non-ribosomal peptide gliotoxin requires significant utilization of cellular sulfur-containing metabolites, GSH and SAM (Figure 2)
Lilly plans to publish the results of its late-stage trial in a peer-reviewed journal
Benefits: Improves skin texture and reduces dark spots, blemishes, and scars
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
PMID 19732754
